MedTrace Logo

Drug-drug Interactions Between DWP14012 and DWC202202 in Healthy Subjects

NCT05574374 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2023-04-04

No results posted yet for this study

Summary

A randomized, open-label, three-sequence, three-period, multiple dosing crossover, phase 1 clinical trial to evaluate the effect of DWP14012 on the pharmacodynamics of DWC202202 in combination with DWP14012 in healthy subjects

Conditions

  • Drug Drug Interaction

Interventions

DRUG

DWP14012

Potassium-competitive acid blocker

DRUG

DWC202202

Clopidogrel Bisulfate

DRUG

DWC202203

Proton pump inhibitor

Sponsors & Collaborators

  • Daewoong Pharmaceutical Co. LTD.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-09-21
Primary Completion
2023-03-06
Completion
2023-03-06

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05574374 on ClinicalTrials.gov